Bausch + Lomb Corporation (TSX:BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of PreserVision® AREDS 2 Formula mini soft gels with OCUSorb™. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, OCUSorb has been clinically shown to provide superior absorption of these nutrients into the body as compared to the original PreserVision AREDS 2 mini soft gel formula.
4D Molecular Therapeutics Q2 EPS $(0.87) Down From $(0.28) YoY
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.87) per share. This is a 210.71 percent decrease over losses of $(0.28) per share from the same period last year.
